Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERROGATE: Biomarker and Genetic Predictors of Erenumab Treatment Response
2019-002331-28Phase 4Completed
- Sponsor
- Amgen
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erenumab in migraine, episodic migraine and chronic migraine, sponsored by Amgen. Primary endpoint: Primary treatment response by genetic biomarkers. Started Jan 2020; status: completed.
02
Drugs
erenumab
03
Conditions
migraineepisodic migrainechronic migraine
Beyond the preview
Go deeper on 2019-002331-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002331-28.